Suflave Shortage: What Providers and Prescribers Need to Know in 2026

Suflave (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride) was FDA approved in June 2023 and quickly gained adoption among gastroenterology practices thanks to its superior palatability and strong clinical efficacy. However, because it is a brand-name-only product without a generic equivalent, providers have begun encountering patient reports of difficulty filling the prescription at local pharmacies.

This guide is designed to help GI providers, internists, and other prescribers understand the current state of Suflave availability, anticipate patient challenges, and have a clinical management plan ready when Suflave cannot be obtained in time for a scheduled colonoscopy.

Current Suflave Availability Status (2026)

As of 2026, Suflave is not listed in the FDA Drug Shortages database. Azurity Pharmaceuticals (manufacturer, marketed by Braintree Laboratories) has not issued any shortage notifications. However, prescribers should be aware of the following practical availability challenges:

• Non-routine stocking at independent and smaller pharmacies: Many pharmacies stock Suflave on an order-on-demand basis only, requiring 2–5 business days lead time.
• Regional variability: Availability varies significantly by region. Areas with higher GI specialist density tend to have better Suflave supply at local pharmacies.
• Insurance friction: Prior authorization requirements and formulary tier placement (typically Tier 3–4) create additional access barriers for some patients.

Clinical Profile: What Makes Suflave Distinctive

Suflave is a 2-liter split-dose prep containing PEG-3350 (178.7 g per bottle), sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride. In two Phase 3 trials:

• Study 1 (vs. MoviPrep-class): 93% success rate vs. 89% for comparator
• Study 2 (vs. SUPREP): 94% success rate vs. 94% for comparator (non-inferiority achieved)
• 79% of patients rated taste as neutral to very pleasant (vs. 54% for SUPREP)
• 80% of patients said they would request Suflave for a subsequent colonoscopy

These metrics make Suflave particularly valuable for patients who have previously declined colonoscopy or expressed hesitancy about the preparation process. Improved palatability has been shown to reduce prep-related procedure cancellations.

Managing Patients Who Cannot Obtain Suflave

When a patient reports difficulty finding Suflave, the clinical priority is preserving the colonoscopy appointment — not the specific preparation agent. Below is a recommended escalation approach:

1. Redirect to higher-volume pharmacies: Direct patients to large chains (CVS, Walgreens, Walmart) or hospital-based pharmacies, which are more likely to stock or rapidly order Suflave.
2. Facilitate a 24-hour order window: Most distributors offer next-day delivery on non-shortage medications. If your patient calls the pharmacy before noon, there's a reasonable chance Suflave will arrive the following day.
3. Switch to an appropriate alternative: If Suflave cannot be obtained in time, prescribe an FDA-approved alternative based on individual patient factors.

Alternative Colonoscopy Preps: Clinical Comparison

• SUPREP (sodium sulfate, potassium sulfate, magnesium sulfate): Closest mechanistic analog to Suflave; widely available; good efficacy (89–94%); taste less palatable than Suflave.
• SUTAB (sodium sulfate, magnesium sulfate, potassium chloride tablets): Tablet form; excellent for patients with strong aversion to liquid preps; 98.1% adequate prep rate in sulfate tablet vs. solution comparison trials.
• Clenpiq (sodium picosulfate, magnesium oxide, citric acid): Smallest volume prep; avoid in patients with CKD, IBD, or electrolyte disturbances; requires stimulant laxative caution in patients on concurrent GI therapies.
• GoLYTELY/NuLYTELY (PEG-3350 with electrolytes): Generic, highly affordable ($10–$40); the safest electrolyte profile for patients with CKD, heart failure, or hyponatremia risk; 4-liter volume is the main tolerability concern.

38,083+ patients found their medications in stock

38K+

Find Suflave In Stock Today →

Key Prescribing Considerations for Suflave

• Electrolyte monitoring: Consider baseline electrolytes and renal function in patients with CKD, heart failure, or on diuretics/ACE inhibitors/ARBs.
• Cardiac risk: Consider pre-dose and post-colonoscopy ECGs for patients with prolonged QT, uncontrolled arrhythmias, recent MI, or cardiomyopathy.
• Drug interactions: All oral medications should be taken at least 1 hour before starting each Suflave dose. Tetracyclines, fluoroquinolones, iron, digoxin, and penicillamine require 2 hours before and 6 hours after each dose (magnesium chelation risk).
• Avoid concurrent stimulant laxatives: Concurrent use of bisacodyl or sodium picosulfate with Suflave increases the risk of ischemic colitis and mucosal ulceration.

Supporting Your Patients: How medfinder Can Help

Consider recommending medfinder for providers to patients who have difficulty finding Suflave. medfinder calls pharmacies in the patient's area to check which ones have the medication in stock and texts the patient results — reducing front-desk burden and minimizing last-minute cancellations due to unfilled prescriptions.